Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS’ Amyvid Final NCD Clarifies Trial Outcomes Goals

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency’s final national coverage determination for beta amyloid positron emission tomography in diagnosing dementia confirms stance the diagnostic will be covered only in trial setting for Medicare, but may offer a little more flexibility in trial design.

You may also be interested in...



Drug Pricing Critic Peter Bach Named Chair Of Medicare Advisory Panel

But appointment unlikely to signal new emphasis on prescription drugs for MedCAC.

Budget Bill Makes End Run Around Medicare Payment Policy For Omidria, Amyvid

Surprise provision directs favorable Medicare Part B reimbursement for a handful of therapeutics beginning later this year.

Lilly Says CMS Review Of Beta-Amyloid PET Goes Beyond Medicare Statutory Criteria

“Improvement in health outcomes” standard would interpret “the statute to require both diagnosis and treatment,” Lilly says about CMS’ recent evaluation of beta-amyloid positron emission tomography in dementia and neurodegenerative disease.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel